ChemLex
Category: AI in Healthcare
An AI-powered drug discovery and chemical synthesis company with 24/7 autonomous chemistry systems that compress months of synthesis into weeks ChemLex was founded in 2022. The company is led by Sean Lin. Based in Singapore, Singapore. Team size: 10-50. Total funding raised: $71 million. Latest round: Series A+. Key investors include Granite Asia, Qiming Venture Partners, LYFE Capital, Sinovation Ventures, MegaRobo.
AMW Analysis
ChemLex operates an AI-powered drug discovery platform that uses autonomous chemistry systems to compress synthesis timelines from months to weeks. The company has raised a total of $71 million, with its latest Series A+ round including investors such as Granite Asia, Qiming Venture Partners, and LYFE Capital. In December 2025, ChemLex secured $45 million to launch a self-driving lab in Singapore, establishing a new global headquarters and scaling its "AI-for-science" initiative. The lab replaces manual wet-lab work with 24/7 continuous robotic operation, integrating AI for hypothesis generation and automated synthesis. This fully autonomous approach aims to dramatically accelerate the R&D cycle for drug and materials discovery. The funding round and lab launch mark a significant infrastructure buildout, positioning Singapore as a hub for deep tech and biomedical innovation. The news flow indicates a shift from computational chemistry toward physical, autonomous experimentation, reflecting ChemLex’s focus on compressing discovery timelines in a market projected to approach $50 billion by 2034.
AMW analysis, generated from 4 tracked news signals.
- Founded
- 2022
- Headquarters
- Singapore, Singapore
- Team size
- 10-50
- Total funding
- $71 million
Value proposition
To accelerate chemical discovery, reduce time-to-market for new drugs, and provide more cost-efficient and sustainable solutions for chemical synthesis through AI-driven automation
Products and solutions
AI-driven automated lab for chemical synthesis, Drug discovery services, Drug development services, Self-driving laboratory platforms
Unique value
24/7 autonomous 'self-driving' lab for chemical discovery that combines AI with robotics and quantum physics, with dedicated servers ensuring client data is never used for AI training
Target customer
Pharmaceutical and biotechnology companies, research institutions
Industries served
Pharmaceuticals, Biotechnology, Chemicals, Materials Science
Technology advantage
Proprietary AI platform that not only speeds up end-to-end synthesis workflows but also predicts and designs smarter, greener synthesis routes, making processes more cost-effective and sustainable than traditional methods
How they differentiate
ChemLex differentiates through its AI-driven automated lab for chemical synthesis and drug discovery, combining AI, quantum physics, and robotics with emphasis on proprietary AI platform and high-throughput automated systems, while guaranteeing clients that their data is not used for training AI models
Main competitors
XtalPi, Isomorphic Labs, Recursion Pharmaceuticals, Insilico Medicine, Schrödinger
Key partnerships
Experimental Drug Development Centre (EDDC), JLABS Asia Pacific (Johnson & Johnson Innovation), Merck KGaA (Merck China) — MOU on automated chemistry / AI-driven R&D (Jan 2026)
Notable customers
Experimental Drug Development Centre (EDDC)
Major milestones
Founded in 2022, Completed $26 million Series A financing in January 2024, Raised $45 million Series A+ funding led by Granite Asia in December 2025, Established global headquarters and self-driving laboratory in Singapore, Supporting 70+ customers worldwide including six of the world's top ten pharmaceutical companies, Signed MOU with EDDC for drug discovery collaboration, Signed MOU with Merck KGaA (Merck China) on automated chemistry and AI-driven R&D (January 2026)
Growth metrics
Serving 70+ customers worldwide; recently established Singapore headquarters with plans to hire more hardware/software engineers and chemists
Market positioning
Next-generation AI-for-science company positioned as a leader in autonomous chemical discovery laboratories, focusing on Asia-Pacific with global ambitions
Geographic focus
Founded in China, established global headquarters in Singapore with strong Asia-Pacific focus and global expansion plans
Patents and IP
Multiple public patents/applications assigned to CHEMLEX PTE. LTD., including granted US 12,649,173 B2 (Container testing equipment, issued Jun 2026) and PCT filings (e.g. WO2026022621A1 filter pressing; WO2026120369A1 drying device/system)
About Sean Lin
MBA from MIT (2015-2017); Previously affiliated with MIT, Imperial College, and Harvard University's Wyss Institute focusing on chemical synthesis automation and AI
Latest news about ChemLex
- ChemLex has secured $45M and launched its self-driving lab in Singapore, dramatically accelerating AI-driven drug discovery. This move positions Singapore as a key hub for deep tech and biomedical inn
- ChemLex secured \$45 million to launch a self-driving lab in Singapore, bringing AI and robotics to drug discovery. This next-generation "AI-for-science" approach completely replaces manual lab work w
- ChemLex has secured $45 million to scale its 'AI-for-science' initiative, establishing a new global headquarters and self-driving lab in Singapore. This investment validates the growing sector of auto
- ChemLex’s launch of a $45M self-driving lab in Singapore marks a pivotal moment, shifting AI from computational chemistry to fully autonomous, physical experimentation. This 24/7 robotic system integr
More AI in Healthcare companies
Official website: https://chemlex.com/
